Key points are not available for this paper at this time.
Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate- and poor-risk patients with previously untreated advanced renal-cell carcinoma. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 214 ClinicalTrials.gov number, NCT02231749 .).
Building similarity graph...
Analyzing shared references across papers
Loading...
Robert J. Motzer
Nizar M. Tannir
Ray McDermott
New England Journal of Medicine
Harvard University
University College London
Brigham and Women's Hospital
Building similarity graph...
Analyzing shared references across papers
Loading...
Motzer et al. (Wed,) studied this question.
www.synapsesocial.com/papers/69d8d0f617a1cc0598d189f6 — DOI: https://doi.org/10.1056/nejmoa1712126